ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Sustained increases in lumbar spine and hip BMD with denosumab therapy beyond 10 years.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDenosumab therapy results in a sustained increase in BMD at the lumbar spine and hip and lower fracture rates during 10 years of treatment. However, data on efficacy and safety beyond 10 years are limited. We present the case of a female who demonstrated a large and continued rise in BMD after 10 years of denosumab therapy. CASE: An 80-year-old woman was referred to our Bone Health Clinic for advice regarding osteoporosis diagnosed 1 year earlier on routine DXA: lumbar spine T-score of -4.2 (0.585 g/cm DISCUSSION: This case illustrates that denosumab therapy beyond 10 years can be associated with significant further increases over a subsequent 3 years in BMD at both the lumbar spine and total hip. This may allow some patients to achieve a desirable treatment target, though future studies on safety and efficacy are needed.
Identifiers
42909485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.